Opinion|Videos|September 30, 2024
NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes
Key Takeaways
- NMIBC management includes TURBT and intravesical therapy, with BCG as a key treatment for higher-risk patients.
- BCG treatment stimulates an immune response, enhancing the body's ability to target bladder cancer cells.
Panelists discuss how standard treatment options for non–muscle-invasive bladder cancer (NMIBC) include BCG therapy, exploring its mechanism of action in enhancing the immune response while also examining management strategies for intermediate and high-risk patients, optimal outcomes with single-agent BCG, and the discrepancies between observed rates of recurrence and progression in clinical practice and reported data.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the standard treatment options for non–muscle-invasive bladder cancer (NMIBC)?
- What are the management options for patients with intermediate and high-risk NMIBC?
- Can you explain the mechanism of action of BCG treatment in stimulating the immune response against bladder cancer?
- In an ideal treatment paradigm with single-agent BCG, what are the best outcomes for patients with high-risk NMIBC?
- What are the rates of recurrence and progression?
- What do you feel the rates of progression are in the real world vs what you see in your practice?
Advertisement
Related to this article
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5